Clinical Trials | September 26, 2025
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
An effectiveness result of 50 per cent achieved during the peak delta variant Covid-19 wave in India, in a highrisk study population of physicians and healthcare workers, in a hospital environment, provides insights into the efficacy and effectiveness of Covaxin
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
Subscribe To Our Newsletter & Stay Updated
